Press Release Date: February 27, 2015
Bioengineers from the esteemed UCLA, have published their work in developing a revolutionary treatment platform that brings a completely personalized approach to cancer treatment.
With over 90 % of unsuccessful cases involving the treatment of metastatic cancer being due to the cancer becoming resistant to the drugs involved in the regime, physicians routinely utilize multiple drugs in their treatment simultaneously, this practice being known as combination therapy. Traditionally the greatest challenge in this style of therapy has been determining the right ratio and combination of the large range of medications currently available is best suited for an individual patient’s needs.
Recently work carried out by researchers Dr. Dean Ho, Professor of oral biology and medicine at UCLA’s School of Dentistry, and his partner Dr. Chih-Ming Ho, Professor of Mechanical Engineering at the University’s Henry Samueli School of Engineering and Applied Science, has resulted in a novel new approach involving the combining of traditional cancer treatment medications and nanotechnology-enhanced drugs to enable far safer and effective treatment regimes to be prescribed. Results from their work have been published under peer review in the journal, ACS Nano.
The paper's co- author, Dr. Chih-Ming Ho and his team have managed to formulate a highly effective means of addressing the problems of drug resistance and dosing in treating cancer sufferers. Feedback System Control.II (FSC.II), as the new tool is known, involves drug efficacy tests and the analysis of cell’s physical traits as well as other biological systems to generate patient specific “maps’ that lay out the safest and most effective drug dosage combinations. The team’s research showed that these drug dosage combinations formulated by FSC.II have the ability to treat multiple lines of breast cancer that featuring drug resistance of varying degrees. The work focused heavily on the most commonly prescribed cancer treatment medications mitoxantrone, doxorubicin, bleomycin and paclitaxel, drugs which are often rendered ineffective due to cancer cells ejecting them before they have a chance to be of benefit.
“This work by Dr. Dean Ho, Dr. Chih-Ming Ho and their team has opened the door to a range of possible treatment solutions involving the use of both nanotechnology delivery systems and establish cancer combating medications. Not only will this aid in safer and more effective treatment of patients who have FSC.II developed regimes, but costs could be substantially reduced by relying on production medications” noted Dr. Eli Stein, ESNano Tech’s COO, and CMO.
Go Back to Press Articles